Related Experiment Video
Updated: Feb 7, 2026

Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma
Published on: July 14, 2022
Inhibitory effect of NVP-BKM120 on cholangiocarcinoma cell growth
Sureerat Padthaisong1,2, Hasaya Dokduang1,2,3, Supak Yothaisong1,2
1Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
Abstract:
Abnormal activation of the phosphatidylinositol 3-kinase (PI3K) pathway has been demonstrated in certain types of cancer, including cholangiocarcinoma (CCA). This pathway may therefore be a promising target for CCA treatment. The present study assessed the inhibitory effect of NVP-BKM120, a pan-class I PI3K inhibitor, on CCA cell growth. This inhibitory effect was determined using CCA cell lines and in CCA-inoculated mice. The result from sulforhodamine B (SRB) assay demonstrated that NVP-BKM120 treatment inhibited CCA cell growth in a dose-dependent manner, even at the lowest tested concentration. The in vivo study revealed that oral administration of NVP-BKM120 (10 or 30 mg/kg) to CCA-inoculated nude mice led to a reduction in tumor growth when compared with controls, which was indicated by an immunohistochemical assay for Ki67 expression. In addition, the result from TUNEL assay demonstrated that NVP-BKM120 induced cancer cell death without any signs of toxicity, which indicated by the body weight of mice (data not shown). Western blot analysis demonstrated that NVP-BKM120 inhibited CCA cell growth by suppressing RAC serine/threonine protein kinase/mechanistic target of rapamycin activation and inhibiting the phosphorylation of phosphatase and tensin homolog, which is the inactivation form of the negative regulator of this pathway. Therefore, the results of the present study indicated that NVP-BKM120 should be considered as a therapeutic agent against CCA that could be used to improve treatment.
Insights
NVP-BKM120, a phosphatidylinositol 3-kinase (PI3K) inhibitor, effectively reduced cholangiocarcinoma (CCA) cell growth and tumor progression in preclinical models. This PI3K inhibitor demonstrated anti-cancer effects without significant toxicity, suggesting its therapeutic potential for CCA treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Aberrant activation of the phosphatidylinositol 3-kinase (PI3K) pathway is implicated in various cancers, including cholangiocarcinoma (CCA).
- Targeting the PI3K pathway presents a potential therapeutic strategy for CCA treatment.
Purpose of the Study:
- To evaluate the efficacy of NVP-BKM120, a pan-class I PI3K inhibitor, in inhibiting CCA cell growth.
- To assess the anti-tumor effects of NVP-BKM120 both *in vitro* and *in vivo*.
Main Methods:
- Sulforhodamine B (SRB) assay to determine *in vitro* cell growth inhibition.
- *In vivo* studies using CCA-inoculated nude mice treated with NVP-BKM120.
- Immunohistochemical analysis for Ki67 expression and TUNEL assay for apoptosis.
- Western blot analysis to investigate pathway modulation.
Main Results:
- NVP-BKM120 significantly inhibited CCA cell growth in a dose-dependent manner *in vitro*.
- Oral administration of NVP-BKM120 reduced tumor growth in CCA-inoculated mice, as evidenced by decreased Ki67 expression.
- NVP-BKM120 induced cancer cell death (apoptosis) without observable toxicity in mice.
- NVP-BKM120 suppressed RAC serine/threonine protein kinase/mechanistic target of rapamycin (mTOR) activation and inhibited phosphatase and tensin homolog (PTEN) phosphorylation.
Conclusions:
- NVP-BKM120 exhibits potent anti-cancer activity against CCA by inhibiting key signaling pathways.
- NVP-BKM120 demonstrates therapeutic potential as a treatment agent for cholangiocarcinoma.
Related Concept Videos
Excitatory and Inhibitory Effects of Neurotransmitters
Cells Coordinate Growth and Proliferation
Population Growth
Meristems and Plant Growth
Primary and Secondary Growth in Roots and Shoots
Relationship Growth

